GlassScriptPhysician profile
Steven D Evans
NPI 1568122000
$6,146.03
in general payments reported to CMS, 2019-2025
28 companies · $2,030 in 2025
The $2,030 reported for 2025 was more than what 91% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $653 · 2023: $1,482 · 2024: $1,981 · 2025: $2,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,358 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,357.72 |
| Education | $134.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,879.66 | 2022-2025 | |
| Janssen Biotech, INC. | $871.11 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Ardelyx, INC. | $531.47 | 2023-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $428.93 | 2022-2025 | Xifaxan |
| Gilead Sciences, INC. | $427.24 | 2023-2024 | Livdelzi, Epclusa |
| Genzyme Corporation | $348.38 | 2023-2025 | |
| Pfizer INC. | $248.10 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $144.11 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Janssen Scientific Affairs, LLC | $138.18 | 2025 | Tremfya |
| Incyte Corporation | $124.48 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $110.81 | 2023-2025 | Dupixent |
| Lilly USA, LLC | $109.22 | 2023-2025 | Omvoh |
| Intra-Sana Laboratories | $100.00 | 2023-2024 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Aimmune Therapeutics, INC. | $99.21 | 2024-2025 | Zenpep |
| Merck Sharp & Dohme LLC | $97.12 | 2023-2024 | Dificid |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $88.16 | 2024-2025 | Voquezna |
| Celltrion USA INC. | $85.44 | 2025 | Vegzelma |
| Ironwood Pharmaceuticals, INC | $62.87 | 2024 | |
| Novo Nordisk INC | $41.00 | 2025 | Wegovy |
| Orphalan INC | $32.54 | 2025 | Cuvrior |
| Boston Scientific Corporation | $31.69 | 2025 | Watchman Flx |
| Organon LLC | $28.11 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $26.25 | 2025 | Iqirvo |
| Redhill Biopharma INC. | $24.16 | 2023 | |
| Intercept Pharmaceuticals, INC. | $21.81 | 2023 | Ocaliva |
| Qol Medical, LLC | $19.43 | 2024 | Sucraid |
| Braintree Laboratories, INC. | $13.40 | 2022 | |
| Celgene Corporation | $13.15 | 2023 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.